» Articles » PMID: 28169606

The Real-life Number of Neonatal Doses of Bacille Calmette-Guérin Vaccine in a 20-dose Vial

Overview
Specialty Public Health
Date 2017 Feb 8
PMID 28169606
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Reducing vaccine wastage is important. Bacille Calmette-Guérin (BCG) vaccine is produced in vials of 20 infant doses. The reconstituted vaccine is discarded after 4-6 hours. Therefore, to reduce vaccine wastage, a 20-dose vial of BCG is often only opened if at least 10-12 infants are present, jeopardising BCG vaccination coverage and timely vaccination. We observed that nurses were not able to withdraw 20 doses from the vials and aimed to quantify how many doses could be obtained from these vials by experienced nurses under real-life circumstances.

Methods: At the maternity ward of the national hospital in Guinea-Bissau, since 2002 the same two nurses have been vaccinating all eligible children with BCG before discharge. During a month in 2015, within a randomised trial comparing BCG-Denmark and BCG-Russia, we registered how many doses the nurses were able to withdraw from the two types of vaccine vials.

Results: The median number of doses which it was possible to withdraw from the vials was 13 (range 11-17): 13 (11-16) for BCG-Denmark (based on 39 vials) and 15 (12-17) for BCG-Russia (based on 29 vials).

Conclusions: In real life, experienced nurses could only obtain 13-15 doses from the 20-dose vials. Thus, vaccine wastage is much lower than assumed. Adjusting practice to the real-life number of doses would immediately suggest vials should be opened if 7 rather than 10 infants are present. As other studies have indicated that BCG may have beneficial non-specific effects on overall mortality, the potential gain by opening a 20-dose vial even for one child may be considerable.

Citing Articles

Non-restrictive open vial policy combined with the home visit vaccinations for improving BCG coverage in a high-incidence outreach region: A model-based cost-effectiveness analysis for Indonesia.

Machlaurin A, Luttjeboer J, Setiawan D, Sytse van der Werf T, Postma M J Glob Health. 2023; 13:04049.

PMID: 37227042 PMC: 10210527. DOI: 10.7189/jogh.13.04049.


BCG skin reactions by 2 months of age are associated with better survival in infancy: a prospective observational study from Guinea-Bissau.

Schaltz-Buchholzer F, Berendsen M, Roth A, Jensen K, Bjerregaard-Andersen M, Sorensen M BMJ Glob Health. 2020; 5(9).

PMID: 32978212 PMC: 7520814. DOI: 10.1136/bmjgh-2020-002993.


BCG as a Case Study for Precision Vaccine Development: Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune Ontogeny.

Angelidou A, Diray-Arce J, Conti M, Smolen K, van Haren S, Dowling D Front Microbiol. 2020; 11:332.

PMID: 32218774 PMC: 7078104. DOI: 10.3389/fmicb.2020.00332.


Design and Optimization of a Temperature-Stable Dry Powder BCG Vaccine.

Price D, Kunda N, Ellis R, Muttil P Pharm Res. 2019; 37(1):11.

PMID: 31873825 DOI: 10.1007/s11095-019-2739-8.


Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance.

Cernuschi T, Malvolti S, Nickels E, Friede M Vaccine. 2017; 36(4):498-506.

PMID: 29254839 PMC: 5777639. DOI: 10.1016/j.vaccine.2017.12.010.

References
1.
Assi T, Brown S, Djibo A, Norman B, Rajgopal J, Welling J . Impact of changing the measles vaccine vial size on Niger's vaccine supply chain: a computational model. BMC Public Health. 2011; 11:425. PMC: 3129313. DOI: 10.1186/1471-2458-11-425. View

2.
Aaby P, Roth A, Ravn H, Napirna B, Rodrigues A, Lisse I . Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?. J Infect Dis. 2011; 204(2):245-52. DOI: 10.1093/infdis/jir240. View

3.
Biering-Sorensen S, Aaby P, Napirna B, Roth A, Ravn H, Rodrigues A . Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J. 2011; 31(3):306-8. DOI: 10.1097/INF.0b013e3182458289. View

4.
Thysen S, Byberg S, Pedersen M, Rodrigues A, Ravn H, Martins C . BCG coverage and barriers to BCG vaccination in Guinea-Bissau: an observational study. BMC Public Health. 2014; 14:1037. PMC: 4195857. DOI: 10.1186/1471-2458-14-1037. View